Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin EEG Neurosci ; : 15500594241263378, 2024 Jul 21.
Artículo en Inglés | MEDLINE | ID: mdl-39034275

RESUMEN

Mismatch negativity (MMN) is automatically elicited by incoming sound deviation compared to the neural representation of preceding homogenous sounds stored in the brain's auditory sensory memory. This study aimed to assess time-functional deviation sensitivity in auditory sensory memory associated with a temporal window of integration (TWI) of 160-170 msec in patients with schizophrenia. To this end, we measured the magnetic counterpart of the MMN (MMNm) in 20 patients with schizophrenia on medication and 20 healthy age-matched adults as a control group responding to an omitted tone segment incorporated into a complex sound of 176 ms duration corresponding to the TWI duration. Overall, the magnitude of the MMNm was smaller in the patients with schizophrenia than in the healthy control group. The peak latency of the MMNm was prolonged in the latter omitted segments for both groups, but to a greater extent in patients with schizophrenia. These results indicate that deviation detection is impaired in the later part of the TWI, corresponding to the duration of auditory sensory memory in patients with schizophrenia. Thus, the specific impairment of MMN in response to duration deviants (duration MMN), as previously reported, might result from a damaged mechanism in the later part of the TWI of sensory memory, suggesting that a decline in sensory memory causes distorted perception or disturbances in cognitive function in patients with schizophrenia.

3.
Hippocampus ; 29(6): 539-549, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30365199

RESUMEN

Neural progenitors acquire GFAP expression during the perinatal period and continue to generate granule cells (GCs) in the hippocampal dentate gyrus throughout adulthood. Cellular characteristics of GFAP+ progenitor-derived late-born GCs in comparison with early-born GCs remain unknown. Using genetic fate mapping in mice, we show that early- and late-born GCs are concentrated in the outer and inner side of the GC layer, respectively. We then identify that a nuclear orphan receptor Nr4A2 is preferentially expressed by early-born GCs. Nr4a2 expression is dynamically regulated in response to restraint stress and glucocorticoid levels, indicating that Nr4a2 is a stress-regulated gene in GCs. Acute stress suppresses but chronic stress conversely induces Nr4a2 expression in GCs. The survival of newly generated GCs is impaired by chronic restraint stress and long-term stress after middle age decreases the proportion of late-born GCs in aged mice. Thus, early- and late-born GCs exhibit characteristic anatomical distribution, differential gene expression, and distinct response to environmental stress.


Asunto(s)
Giro Dentado/metabolismo , Miembro 2 del Grupo A de la Subfamilia 4 de Receptores Nucleares/genética , Envejecimiento/genética , Envejecimiento/metabolismo , Animales , Giro Dentado/citología , Giro Dentado/crecimiento & desarrollo , Regulación del Desarrollo de la Expresión Génica , Glucocorticoides/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Células-Madre Neurales/citología , Células-Madre Neurales/metabolismo , Neurogénesis/genética , Neurogénesis/fisiología , Restricción Física , Estrés Fisiológico
4.
Medicine (Baltimore) ; 97(33): e11449, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-30113451

RESUMEN

INTRODUCTION: Multicentric reticulohistiocytosis (MRH) is a rare histiocytic disorder that involves the skin, joints, and visceral organs. CASE PRESENTATION: We report a 67-year-old woman with MRH who presented with a 2-years history of polyarthralgia and skin nodules. Her symptoms were an inflammatory polyarthropathy with punched-out lesions of the distal interphalangeal (DIP) joints of both hands. Doppler ultrasonography of the hands showed large bone erosions with power Doppler signals in the DIP joints. F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) demonstrated increased FDG uptake in cutaneous papules surrounding the affected joints, suggesting an inflammatory process. There was no evidence of malignancy. Biopsy samples of skin nodules exhibited dermal infiltration with CD68-positive histiocytes and multinucleated giant cells. The patient was diagnosed with MRH and treated with combination therapy comprising a steroid (prednisolone), tacrolimus, methotrexate, and infliximab, which resulted in clinical improvement. Following infliximab treatment, there was a significant decrease in a bone resorption marker (tartrate-resistant acid phosphatase 5b: TRACP-5b), suggesting that tumor necrosis factor-α targeting therapy may inhibit osteoclast formation and resorption activity in patients with MRH. CONCLUSION: MRH is a progressive destructive arthritic condition, and early diagnostic and therapeutic strategies are necessary to improve the outcome. FDG-PET/CT and joint ultrasonography might be noninvasive imaging modalities that could help diagnose MRH.


Asunto(s)
Artralgia/diagnóstico por imagen , Fluorodesoxiglucosa F18/metabolismo , Histiocitosis de Células no Langerhans/diagnóstico por imagen , Tomografía Computarizada por Tomografía de Emisión de Positrones/métodos , Piel/diagnóstico por imagen , Anciano , Antígenos CD/metabolismo , Antígenos de Diferenciación Mielomonocítica/metabolismo , Antirreumáticos/uso terapéutico , Pueblo Asiatico/etnología , Combinación de Medicamentos , Femenino , Glucocorticoides/uso terapéutico , Mano/diagnóstico por imagen , Mano/patología , Histiocitos/inmunología , Histiocitos/patología , Histiocitosis de Células no Langerhans/tratamiento farmacológico , Histiocitosis de Células no Langerhans/patología , Humanos , Inmunosupresores/uso terapéutico , Infliximab/administración & dosificación , Infliximab/uso terapéutico , Metotrexato/administración & dosificación , Metotrexato/uso terapéutico , Prednisolona/administración & dosificación , Prednisolona/uso terapéutico , Piel/metabolismo , Piel/patología , Tacrolimus/administración & dosificación , Tacrolimus/uso terapéutico , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/efectos de los fármacos , Ultrasonografía Doppler/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA